An Update on the Use of Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
- 1 March 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Cancer Journal
- Vol. 15 (2), 105-109
- https://doi.org/10.1097/ppo.0b013e31819e31f2
Abstract
The intraperitoneal delivery of chemotherapy as a strategy to manage epithelial ovarian cancer has been extensively examined in both the preclinical and clinical settings. Several randomized phase 3 trials have documented improved survival associated with regional versus systemic delivery of cisplatin in the primary chemotherapeutic management of small volume residual advanced ovarian cancer. Unfortunately, despite the existence of these evidence-based data, this management strategy remains underutilized. Future research efforts are mandated to develop regimens which improve the toxicity profile of this novel method of treatment while maintaining the documented enhanced efficacy of the approach.Keywords
This publication has 28 references indexed in Scilit:
- Intraperitoneal chemotherapy and the NCI clinical announcementGynecologic Oncology, 2006
- Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxelGynecologic Oncology, 2006
- Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime TimeJournal of Clinical Oncology, 2006
- Intraperitoneal Chemotherapy in Ovarian Cancer Remains ExperimentalJournal of Clinical Oncology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal antineoplastic drug delivery: rationale and resultsThe Lancet Oncology, 2003
- Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2001
- Intraperitoneal drug delivery of antineoplastics.Drugs, 2001
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.Journal of Clinical Oncology, 1992